H ypertrophic cardiomyopathy (HCM) is currently defined as a genetic cardiovascular disease with a primary defect in the sarcomeric proteins. 1 It is characterized by the presence of myocardial hypertrophy, interstitial fibrosis, myofibrillar disarray, diastolic dysfunction, and increased susceptibility to arrhythmias. 2,3 HCM shows autosomal-dominant inheritance in the vast majority of the cases and has been linked to more than a thousand mutations in ≥9 genes encoding components of the sarcomere. [4] [5] [6] [7] The affected proteins include the thick filament proteins: myosin heavy chain, myosin binding protein C, regulatory (LC2), and essential myosin light chain, as well as the thin filament proteins: α-actin, troponin (Tn) complex protein, troponin T, troponin I (TnI), troponin C, α-tropomyosin, and titin along with other Z-disk-related proteins. 8-10
Ca 2+ -channel blockers, antiarrhythmic drugs, diuretics, cardiac implantable defibrillators, and heart transplantations. 12 More recent experimentation in animal models of HCM has provided potential new therapies, which include statins, renin-angiotensin-aldosterone system inhibitors, and N-acetylcysteine [13] [14] [15] [16] [17] [18] [19] ; however, further animal studies are required to develop and validate more specific treatments for individual cases. We and others previously reported that improving the rate of relaxation from the levels dictated by thin filament protein mutations in HCM mouse models, by either interventions in the rate of sarcoplasmic reticulum Ca 2+ uptake 20, 21 or by increasing the expression of parvalbumin, a cytoplasmic Ca 2+ -binding protein, 22 improved the cardiac function of HCM animals. These data strongly support the idea that improving relaxation rates may be a potential new therapeutic target for HCM.
In addition to interventions in Ca 2+ flux regulation or buffering, another, more direct way to improve relaxation in HCM is to directly target the myofilaments and reduce their sensitivity to Ca 2+ . Although currently there are no approved drugs that specifically desensitize myofilament to Ca 2+ , our and other previous works have demonstrated that one way to reduce sensitivity is by protein kinase A-mediated cTnI phosphorylation at Ser23 and Ser24, which decreases the myofilament Ca 2+ response and increases the kinetics of myocardial relaxation. [23] [24] [25] [26] [27] [28] To prove this concept, we used mice that express TnI pseudophosphorylated at the PKA phosphorylation sites (Ser23 and Ser24 were mutated to Asp; TnI-PP) and showed decreased myofilament Ca 2+ sensitivity. 28 Although pseudophosphorylation does not always mimic phosphate incorporation, we and others have demonstrated the mutation of TnI Ser23/24 residues to the negatively charged Asp residues function both structurally and functionally identical to the effects of PKA-mediated negative charged phosphate incorporation into TnI Ser23/24 of cardiac muscle. [28] [29] [30] [31] For the current study, we crossed TnI-PP mice 28 with mice that expressed mutated Tm at position 180 (E180G or Tm180) linked to HCM. 32 The Tm180 mice exhibit increased myofilament Ca 2+ sensitivity, diastolic dysfunction, and cardiac hypertrophy in accordance with the main aspects of the human disease. 20, 21, 32 We found that Tm180 mice expressing TnI-PP (double transgenic [DTG] mice) were rescued from pathological cardiac remodeling and further displayed improved left ventricular (LV) performance when compared with Tm180 littermates expressing wild-type TnI. Our results strongly suggest that myofilament desensitization to Ca 2+ is a viable novel therapeutic strategy for the treatment of HCM linked to thin filament protein mutations.
Methods
For more detailed methods, see the Data Supplement.
Generation of New TG Mice
New transgenic (TG) mouse lines were generated by crossbreeding existing lines of mice: Tm180 32 and TnI-S23,24D (TnI-PP) 28 mice. All mice used in this work were in the FVBN genetic background. Four groups of mice were used for experiments: (1) nontransgenic (NTG), which express wild-type Tm and TnI; (2) TnI-PP, which express wild-type Tm and TnI-PP; (3) Tm180, which express Tm180 and wild-type TnI; and (4) Tm180/TnI-PP (DTG), which express Tm180 and TnI-PP.
All animal procedures were conducted according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Review Board of the University of Illinois at Chicago.
pCa-Force Relationship in Skinned Fiber Preparation
Measurements of pCa-force relations were performed as previously described. 33 
Whole Troponin Complex Exchange in Skinned Fiber Preparation
Cloning and whole troponin exchange in skinned fiber preparation were done as previously described. 34 For skinned fiber experiments, the bundles from NTG or Tm180 hearts were obtained as described above.
Echocardiography
Echocardiography was performed using a Vevo 770 High-Resolution In Vivo Imaging System and RMVTM 707B scan head with a center frequency of 30 MHz (VisualSonics, Toronto, ON, Canada) as previously described. 20 Echocardiographic studies were performed in each animal at 1, 2, 8, and 14 weeks after birth.
Langendorff Perfused Hearts
LV function was measured in 6-week-old animals as previously described. 35 
In Situ Hemodynamic
In situ pressure-volume measurements were performed in 14-week-old mice as previously described. 20
Histology
The histology was done in heart section from 14-week-old mice as previously described. 20
Western Blots
The Western blots were performed as previously described 20, 36, 37 with slight modifications.
Assessment of Myofilament Phosphorylation by Pro-Q Diamond Stain
Assessment of myofilament phosphorylation was performed as previously described 38 with slight modifications.
Hydroxyproline Assay
Hydroxyproline content was determined as previously described. 21
Statistical Analysis
All statistical analysis was performed using GraphPad Prism 6. Data in the manuscript are presented as mean±SE, and n indicates number of samples. In addition to graphical representation of data, numeric mean±SD are presented in Tables in the Data Supplement. Differences among 4 groups were analyzed by 1-way analysis of variance followed by post hoc analysis using Tukey or Fisher Least Significant Difference tests. The name of the post hoc test used is specified in figure legends, table legends, or in the text. Explicit values for significance are given in the Data Supplement. When only 2 isolated groups were compared, Student t test was used. Differences were considered significant when P<0.05.
Results

TnI Pseudophosphorylation Reduces Myofilament Sensitivity to Ca 2+
To determine the potential level of myofilament desensitization caused by pseudophosphorylation of TnI at Ser23,24, we performed exchange experiments in fiber bundles prepared from NTG and Tm180 hearts. This method allows ≈70% exchange of endogenous with exogenous troponin complex. 39 We exchanged native Tn in detergent skinned fibers from Tm180 and NTG hearts with a Tn complex reconstituted with either unphosphorylated TnI (wtTnI) or pseudophosphorylated TnI (TnI-S23,24D). Figure 1 shows that NTG and Tm180 myofilaments reconstituted with TnI-S23,24D were less sensitive to Ca 2+ (rightward shift) compared with myofilaments reconstituted with wtTnI (pCa 50 =5.62±0.01 NTG[wtTnI], pCa 50 =5.43±0.01 NTG[TnI-S23,24D], pCa 50 =5.84±0.01 Tm180[wtTnI], and pCa 50 =5.60±0.01 Tm180[TnI-S23,24D]; n=8). Interestingly, Tm180 myofilaments reconstituted with TnI-S23,24D showed only a slightly smaller sensitivity and a similar cooperativity (Hill coefficient) as NTG myofilaments reconstituted with wtTnI.
Expression of TnI-PP Prevents Tm180 Hearts From Pathological Remodeling
High-resolution echocardiography and gross pathology evaluation demonstrated that Tm180 hearts developed cardiac chamber remodeling that was rescued by expression of TnI-PP ( Figures 2 and 3) . Figure 2A and 2B shows that Tm180 hearts displayed significantly enlarged left atria as early as 2 weeks, and atrial size was lower or normal in Tm180 hearts expressing TnI-PP. Figure 2C to 2F shows that Tm180 hearts displayed severe LV concentric hypertrophy (increased septal wall thickness with unaltered LV internal diastolic dimension, higher LV mass, and higher heart weight to tibia length) ratio that was not seen in DTG hearts. Histological studies of Tm180 heart sections demonstrated marked myocardial disarray, myocyte hypertrophy, and higher collagen deposition in the extracellular matrix compared with all other groups ( Figure 3 ). When compared with NTG, DTG hearts also displayed higher collagen content in the extracellular matrix, but this was seen to a lesser degree than in Tm180 hearts ( Figure 3B ). Collagen content was also determined by hydroxyproline assay. Figure 3C shows that hydroxyproline content was significantly higher in Tm180 hearts compared with NTG (11.07±1.17 μmol/mg [n=5] versus 7.27±1.28 μmol/mg [n=5]) but was normal in DTG hearts (7.07±1.38 μmol/mg [n=5]).
TnI-PP Prevents the LV Dysfunction Seen in Tm180 Hearts
Serial echocardiography and Doppler studies showed that Tm180 mice developed severe diastolic dysfunction. Figure 4 summarizes the evaluation of the diastolic function by pulsed and Tissue Doppler Imaging (TDI) studies in all 4 groups of mice at different ages. The mitral inflow pattern showed impaired relaxation of the LV with lower E/A ratio and prolonged isovolumic relaxation time in 1-week-old Tm180 mice, which progressed to a restrictive pattern of LV filling with high E/A ratio, normal isovolumic relaxation time, and E wave DT in 8-week-old mice ( Figure 4B-4D ). Peak myocardial velocity in the early phase of diastole (E m ), assessed by TDI, was lower in Tm180 mice compared with NTG and TnI-PP mice, which confirmed early LV impaired relaxation ( Figure 4E ). Peak myocardial velocity in late diastole (A m ) was lower and the E/E m ratio was higher in Tm180 hearts after 8 weeks when compared with NTG, suggesting a progressive decrease of the LV compliance and increased filling pressure ( Figure 4F and 4G). Importantly, the mitral inflow pattern and TDI-derived indexes demonstrated that the diastolic function was normal in DTG mice.
Systolic function, as assessed by ejection fraction, was preserved in Tm180 mice until 14 weeks (NTG=62.4±2.5% [n=8], TnI-PP=62.0±3.8% [n=8], Tm180=63.9±2.5% [n=8], and DTG=70.9±2.7% [n=6]). However, at this age, systolic peak myocardial velocity (S m ) was lower in Tm180 mice when compared with NTG (17.6±0.7 versus 21.7±0.3 cm/s, respectively), suggesting impaired myocardial contractility. This finding was not observed in DTG mice (S m =21.8±0.6 cm/s), which was not significantly different from NTG.
We also evaluated the LV performance of isolated hearts from 6-week-old mice in Langendorff preparations ( Figure 5 ; Table III in the Data Supplement). The LV performance was studied at baseline conditions and after stimulation with 25 nmol/L of isoproterenol. Although at this age the basal contractile parameters were not significantly different in Tm180 hearts compared with NTG ( Figure 5A-5C ), after stimulation with isoproterenol, LV developed pressure and +dP/ dt were significantly lower in Tm180 hearts compared with NTG ( Figure 5D and 5E), indicating a reduced capacity of the Tm180 hearts to adapt to increased contractile demand. Moreover, the −dP/dt was lower in 6-week-old Tm180 mice compared with NTG ( Figure 5F ), which denotes an impaired lusitropic response to stress. However, age-matched DTG mice showed normal LV performance at rest and adequate inotropic and lusitropic responses to stress, as denoted by LV developed pressure, +dP/dt and −dP/dt, both at rest and after stimulation with isoproterenol.
We also used a P-V conductance catheter to perform hemodynamic studies in 14-week-old mice ( Figure 6 ; Table IV in the Data Supplement). Tm180 mice showed normal values for ejection fraction and +dP/dt but lower preload recruited stroke work and end-systolic pressure-volume relation, a load-independent parameter of contractility. The diastolic function was impaired in Tm180 mice as assessed by the load-dependent parameters −dP/dt and τ and by the load-independent parameter end-diastolic pressure-volume relation. However, there was no significant difference in end-diastolic pressure between groups. These abnormalities of myocardial contractility and relaxation resulted in reduced hemodynamic performance in Tm180 hearts, as demonstrated by the lower cardiac output in Tm180 mice compared with NTG. Importantly, myocardial contractility was normal in age-matched DTG mice, with the Table I mean values of +dP/dt, end-systolic pressure-volume relation and preload recruited stroke work showing no differences from NTG mice. Despite the fact that DTG mice showed a lower relaxation rate (lower -dP/dt compared with NTG), this diastolic abnormality was less pronounced than in Tm180. Furthermore, the load-independent parameter end-diastolic pressure-volume relation in DTG mice was not significantly different from NTG. Overall, cardiac performance was normal in DTG mice, as can be seen by the normal values of cardiac output.
Expression of TnI-PP in Tm180 Mice Reduces Myofilament Ca 2+ Sensitivity
In the exchange experiments, we observed that myofilament sensitivity to Ca 2+ is significantly lower when fibers were exchanged with TnIS23,24D compared with fibers exchanged with wtTnI, independent of whether the fibers were prepared from 14-week-old NTG or Tm180 hearts. To test the degree to which these findings are similar in a more physiologically relevant system, we also evaluated the degree of desensitization in skinned fibers prepared from NTG and Tm180 mouse hearts expressing either wild-type TnI or TnI-PP (Figure 7) . The pCa-force relations showed that myofilaments from TnI-PP hearts had a lower Ca 2+ sensitivity (pCa 50 =5.79±0.01; n=6) than NTG (pCa 50 =5.85±0.01; n=6), whereas Tm180 hearts had higher Ca 2+ sensitivity (pCa 50 =6.04±0.02; n=6). The Ca 2+ sensitivity of fibers from DTG hearts (pCa 50 =5.97±0.01; n=6) was significantly lower than Tm180 and was observed somewhere between the sensitivities for Tm180 and NTG fibers. The Hill coefficient, an indicator of cooperativity or steepness of the pCa-force relationship, was lower in Tm180 and DTG fibers when compared with their matched controls, NTG and TnI-PP, but there were no differences in the maximal generated tensions (data not shown).
Because Tm180 and TnI-PP were coexpressed in DTG mice, we assessed the levels of expression of Tm180 in Tm180 and DTG hearts. There were no significant differences in Tm180 expression between hearts from Tm180 and DTG mice (63.08±4.79% [n=4] versus 62.56±3.69% [n=4], respectively). Also, the total Tm expression was not different among the 4 groups of animals (normalized to actin, in arbitrary units: NTG=0.68±0.07, TnI-PP=0.70±0.06, Tm180=0.78±0.08, and DTG=0.79±0.06, n=5 for each group). Because the reduction in myofilament Ca 2+ sensitivity caused by expression of TnI-PP in Tm180 mice was smaller than the decreased myofilament sensitivity caused by exchange of wtTnI by TnI-PP (Figure 1 ), we also assessed the level of expression of TnI-PP in TnI-PP and DTG mice, as well as the levels of myofilament phosphorylation. There were no significant differences in TnI-PP expression between hearts from TnI-PP and DTG 
Total Expression of Serca2 and Phospholamban Is Unaltered, but the Phosphorylation Level of Phospholamban Is Higher in DTG Compared With Tm180
Because the rate of cardiac relaxation depends on the Ca 2+ uptake by the sarcoplasmic reticulum, we assessed the expression of Serca2 and phospholamban at 14 weeks. There were no changes in expression of either protein among the 4 groups of mice (data not shown), but we found that the level of phospholamban phosphorylation at the PKA site, Ser16, was higher in DTG mice compared with Tm180 (see the Data Supplement). Figure 8A shows that the level of phosphorylation of ERK1/2 was higher in Tm180 hearts compared with control groups and that phosphorylation was normal in DTG mice (NTG=0.61±0.12, TnI-PP=0.63±0.14, Tm180=1.69±0.39, DTG=0.99±0.14; n=7). The level of GATA4 phosphorylation was also higher in Tm180 compared with control groups, along with normal level in DTG hearts (NTG=0.37±0.06, TnI-PP=0.55±0.14, Tm180=1.18±0.26, DTG=0.65±0.13; n=6). There were no observed differences in the activation of the serine/threonine kinase Akt or GSK3α/β among groups.
Expression of TnI-PP in Tm180 Hearts Results in Normal Activity of ERK1/2 and GATA4
Discussion
Experiments reported here are the first to show that a partial and sustained decrease of myofilament Ca 2+ sensitivity, by expression of pseudophosphorylated TnI, in an HCM mouse model linked to a Tm mutation can completely prevent the development of the hypertrophic phenotype and improve cardiac function. F) , and E to E m ratio (E/E m ; G). Tm180 hearts showed decreased E m in all ages, decreased A m , and increased E/E m ratio after 2 weeks, suggesting early impaired relaxation and progressive decrease in left ventricular compliance. DTG hearts showed mitral inflow and TDI patterns similar to NTG controls. Data are presented as mean±SE. *Significantly different from NTG; †significantly different from DTG; and ‡significantly different from Tm180 based on post hoc multiple comparison analysis (Tukey test). Numeric data and P values for significance are presented in Table II in the Data Supplement. n=4 to 8 per group.
Most of the mutations in thin filament proteins linked to HCM consistently show increased myofilament sensitivity to Ca 2+ , resulting in diastolic dysfunction and eventual late progression to systolic dysfunction. 9, 40, 41 Therefore, correcting the relaxation properties in HCM through desensitization of the myofilaments seems to be a straightforward and logical approach. We have shown previously that decreasing myofilament Ca 2+ sensitivity in Tm180 hearts by expression of chimeric α/β-Tm rescued the hypertrophic phenotype and improved cardiac function. 42 The major limitation of these studies was that by crossing 2 TG mouse models with changes in Tm, we generated DTG mice that not only had a decreased myofilament Ca 2+ sensitivity compared with Tm180 mice but also expressed lower levels of mutated Tm180. Therefore, the prevention of the hypertrophic phenotype could have been attributed to both a decreased myofilament Ca 2+ sensitivity and a lower level of expression of mutated Tm180. This was not the case in the present study, as the reduction in Ca 2+ sensitivity occurred without changes in the expression level of Tm180. Similar studies have also been performed by Li et al. 43 The authors corrected diastolic dysfunction caused by a mutation in TnI by expressing a truncated TnI. However, Li et al 43 did not use an HCM but rather a restrictive cardiomyopathy mouse model that showed only mild diastolic dysfunction without hypertrophy and only a slight increase in left atria size. In our studies, we used a mouse model with severe hypertrophy, fibrosis, and diastolic dysfunction present as early as 1 week that progressed to severe diastolic dysfunction as early as 2 weeks (Figure 4 ). Moreover, our goal was to desensitize the myofilaments without altering the expression of mutated Tm to make the studies more clinically relevant and as a proof of concept that treatment of HCM with desensitizers should be considered as a potential new treatment. TnI has been recognized as an important regulatory protein for Ca 2+ -mediated thin filament activation, 44, 45 and furthermore, phosphorylation of TnI at Ser23/24 reduces the myofilament Ca 2+ sensitivity. 46, 47 This makes TnI an excellent potential target for the development of Ca 2+ desensitizers. Moreover, the mechanism of action for some Ca 2+ sensitizers is through TnC-TnI, 48 suggesting the possibility that development of Ca 2+ desensitizers could also target TnI. To test the hypothesis that expression of pseudophosphorylated TnI at Ser23/24 can successfully desensitize Tm180 myofilaments to Ca 2+ , we performed exchange experiments in which native TnI was replaced by either TnI-S23,24D or wtTnI in skinned fibers from NTG and Tm180 hearts (Figure 1 ). We found that replacement of Tm180 myofilaments with a Tn complex possessing TnI-S23,24D successfully desensitized them to Ca 2+ . This would suggest that our DTG Table III in the Data Supplement. n=4 to 5 per group.
mice, which express Tm180 and TnI-PP, should also show normalized myofilament Ca 2+ sensitivity. However, skinned fiber data from DTG mice showed only partial restoration of myofilament Ca 2+ sensitivity (Figure 7 ). This can be because of differences in post-translational modifications of myofilaments between different groups of mice. For example, we found that there was a trend toward higher LC2 phosphorylation in DTG compared with Tm180 mice (Data Supplement). It is well documented that phosphorylation of LC2 results in increased myofilament Ca 2+ sensitivity and can balance the decrease caused by increasing TnI phosphorylation at PKA sites. 49 Overall our data indicate that either small desensitization is sufficient to prevent the development of a hypertrophic phenotype or that additional compensatory mechanisms are present in DTG mice and contribute to the observed rescue of the Tm180 phenotype. We have shown previously that increasing sarcoplasmic reticulum Ca 2+ uptake can rescue Tm180 hearts 21 ; therefore, we tested whether expression of Serca2a and phospholamban proteins or phosphorylation of phospholamban is altered in DTG mice compared with other groups. We found no changes in Serca2a and phospholamban expression or phospholamban phosphorylation at Thr17 among groups. However, Ser16 phosphorylation of phospholamban was increased in DTG mice compared with the other groups, suggesting that the increase in sarcoplasmic reticulum Ca 2+ uptake may also contribute to the prevention of the hypertrophic phenotype. Based on these findings, we postulate that there is a range of myofilament sensitivity to Ca 2+ that one could consider as a homeostatic safe zone. Our data suggest that if the use of Ca 2+ desensitizers could bring the myofilament Ca 2+ sensitivity into this homeostatic range, then this would be of therapeutic benefit in preventing the development of the hypertrophic phenotype in HCM caused by mutations in thin filament proteins. It is important to note, however, that exacerbated desensitization of the myofilament has the potential to cause a reduction in systolic function and may ultimately lead to systolic heart failure, although this was not observed in our mouse model. This idea of a safe zone of myofilament Ca 2+ sensitivity is also indirectly supported by other studies. It is known that the myofilament Ca 2+ sensitivity changes as a result of phosphorylation of the myofilament proteins, not only in pathological conditions as a result of adaptation or maladaptation but also during physiological conditions such as exercise. 50 Several in vitro studies have shown that phosphorylation of TnI by PKA can shift the myofilament Ca 2+ sensitivity as much as 0.2 pCa units, 46 ,51 suggesting that similar changes occur in vivo. Also, we have shown previously that another TG mouse model of HCM with the mutation D175N in Tm, which shows a small relative increase of myofilament sensitivity to Ca 2+ , also demonstrates only a small relative degree of diastolic dysfunction and almost no hypertrophy. 52 This suggests that the myofilaments and hearts from TmD175N mice operate near this safe zone of Ca 2+ sensitivity.
The reduction in myofilament Ca 2+ sensitivity in Tm180 mice not only resulted in improvement of heart morphology and function but also prevented the altered activity of ERK1/2 and GATA4. The increased activity of ERK1/2 in an HCM transgenic rabbit model caused by a mutation in β-MHC has been reported previously. 18 We have also shown this previously in the Tm180 mouse model, in which the increased phosphorylation of ERK1/2 seen could be prevented by phospholamban knockout. 20 This finding suggests that an intervention in Ca 2+ regulation and correction of relaxation contributes to the observed restoration of ERK1/2 activity. However, our current data show that correction of relaxation by desensitization of the myofilaments, without major changes in SERCA or phospholamban expression, also prevented the ERK1/2 modifications. The involvement of ERK1/2 signaling along with Jun amino-terminal kinase (JNK1) and p38 kinases in the development of hypertrophy is well documented. 53 Recently, Kehat et al 54 reported that ERK1/2 uniquely regulates the balance between eccentric and concentric growth of the heart, suggesting that elevations in ERK1/2 activity simultaneously inhibits addition of new sarcomeres in series while promoting addition of new sarcomeres in parallel. It is possible that ERK1/2 activation depends on both the kind of stimulus (pressure versus volume overload or genetically linked HCM) and the changes that occur during the course of disease development. In addition to the improvement in morphology and cardiac function in Tm180 mice, desensitization of myofilaments to Ca 2+ in HCM could have an additional beneficial effectreduction of the susceptibility to arrhythmia. Increased myofilament sensitivity to Ca 2+ increases the risk of arrhythmia, and, therefore, reduction of Ca 2+ sensitivity would be antiarrhythmic. 55 In as much as DTG mice hearts show decreased fibrosis and reduced myofilament Ca 2+ sensitivity, they also should be less sensitive to arrhythmia. More experiments, which are beyond the scope of the present experiments, are required.
In summary, we have demonstrated that desensitization of myofilaments to Ca 2+ should be considered as a new and promising therapeutic intervention for HCM caused by a mutation in thin filament proteins and that TnI may be an important target for the development of myofilament Ca 2+ desensitizers. A similar approach also may be adequate in cases of HCM caused by gene mutations in thick filament or Z-disc proteins, but more studies would be required when specific myofilament Ca 2+ desensitizers become available. 
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